[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Varghese BT, Ramdas K, Sebastian P, Nair MK: Salvage chemotherapy and surgery for radio recurrent carcinoma glottis. Indian J Cancer; 2003 Jul-Sep;40(3):113-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy and surgery for radio recurrent carcinoma glottis.
  • They include histologically confirmed recurrent or residual disease or a symptomatic life threatening treatment sequelae.
  • Tumour recurrence or residivism can be managed by chemotherapy when radical surgery is either refused by the patient or if the general condition of the patient do not permit it.
  • However surgery becomes inevitable when life threatening treatment sequelae like absolute pharyngo-oesophageal stricture and aspiration sets in.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Radiation-Induced / drug therapy. Salvage Therapy
  • [MeSH-minor] Combined Modality Therapy. Esophageal Stenosis / etiology. Esophageal Stenosis / surgery. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14716115.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Ishihara S, Kubota S, Itoh J, Fujimoto Y, Nakashima T, Naganawa S: Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis. Head Neck Oncol; 2010 Jul 30;2:20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis.
  • BACKGROUND: To assess the results for local control (LC) and survival in patients with early-stage glottic cancer (GC) who were treated by radiotherapy (RT) with or without chemotherapy.
  • METHODS: Fifty-eight patients with T1-T2 squamous cell carcinoma of the glottis who were treated between 2001 and 2006 were analyzed retrospectively.
  • Of the 58 patients, eight developed recurrent disease at the primary site, and one had lymph node recurrences on the neck.
  • CONCLUSIONS: The retrospective analysis showed a high rate of LC and larynx preservation in patients with T1-T2 GC by means of RT with or without chemotherapy.
  • There was, however, no statistical difference in LC rates for the two types of therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Glottis / pathology. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):21-6 [10656367.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1104-9 [18950960.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4029-36 [11600604.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):109-19 [11777628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):415-9 [11872287.001]
  • [Cites] Head Neck. 2002 Jul;24(7):637-42 [12112536.001]
  • [Cites] Int J Cancer. 2002 Aug 1;100(4):472-5 [12115532.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):471-8 [12243824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):322-8 [12527044.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):765-72 [12910521.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):313-7 [3104243.001]
  • [Cites] Radiother Oncol. 1998 May;47(2):161-6 [9683364.001]
  • [Cites] Laryngoscope. 1998 Dec;108(12):1853-5 [9851503.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1378-86 [16095847.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1387-94 [16115737.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):77-82 [16169681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):995-1001 [16406396.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3693-704 [16832122.001]
  • [Cites] Radiat Med. 2006 May;24(4):277-81 [16958401.001]
  • [Cites] Oncology. 2006;71(5-6):369-73 [17851262.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5B):3497-500 [17972507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1389-94 [17869013.001]
  • [Cites] Auris Nasus Larynx. 2008 Jun;35(2):213-9 [17996416.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):723-35 [11020569.001]
  • (PMID = 20673360.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2919535
  •  go-up   go-down


3. Vachin F, Hans S, Atlan D, Brasnu D, Menard M, Laccourreye O: [Long term results of exclusive chemotherapy for glottic squamous cell carcinoma complete clinical responders after induction chemotherapy]. Ann Otolaryngol Chir Cervicofac; 2004 Jun;121(3):140-7
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long term results of exclusive chemotherapy for glottic squamous cell carcinoma complete clinical responders after induction chemotherapy].
  • [Transliterated title] Résultats à long-terme de la chimiothérapie exclusive des cancers épidermoïdes glottiques.
  • OBJECTIVES: To evaluate the long-term results of exclusive chemotherapy for T1-T3N0M0 glottic squamous cell carcinoma complete clinical responders after induction chemotherapy.
  • MATERIAL AND METHODS: Between 1985 and 2000, 69 patients with glottic squamous cell carcinoma complete clinical responders after induction chemotherapy were managed with exclusive chemotherapy at our department.
  • Chemotherapy associated platinum and fluorouracil.
  • This retrospective analysis evaluated actuarial survival, treatment morbidity, oncologic events and laryngeal preservation.
  • Chemotherapy never resulted in death.
  • CONCLUSION: Altogether our data and the review of the literature suggest that in patients achieving a complete clinical response after and induction based chemotherapy regimen, the completion of an exclusive chemotherapy regimen appears to be a valid alternative to the conventional use of radiotherapy or chemo-radiation protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Glottis / pathology. Laryngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Outcome Assessment (Health Care). Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15223999.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Alieva SB, Tkachev SI, Romanov IS, Zaderenko IA, Tiuliandin SA: [Docetaxel as a component in the combined therapy of locally advanced squamous cell carcinoma of the glottis and oral cavity]. Vopr Onkol; 2010;56(5):597-602
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Docetaxel as a component in the combined therapy of locally advanced squamous cell carcinoma of the glottis and oral cavity].
  • Two modalities of chemoradiotherapy for locally advanced squamous cell cancer of oro-hypopharynx and oral cavity were compared in the treatment of 34 patients.
  • Five-year survival after cisplatin, 5-FU, taxotere, and carboplatin plus irradiation with TTD of 68-72 Gy (group 1) was 59.5% versus 13.8% without taxotere (group 2).
  • Post-therapeutic complication stage III-IV was 57.8% (group 1) and 48% (group 2).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Glottis. Laryngeal Neoplasms / drug therapy. Mouth Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Platinum Compounds / administration & dosage. Radiotherapy, Adjuvant / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21137242.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Platinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Murakami R, Nishimura R, Baba Y, Yumoto E, Oya N, Yamashita Y: Concurrent chemoradiation therapy with low-dose CDDP and UFT for glottic carcinomas: evaluation using the sixth edition of the UICC TNM staging system. Acta Oncol; 2006;45(2):162-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation therapy with low-dose CDDP and UFT for glottic carcinomas: evaluation using the sixth edition of the UICC TNM staging system.
  • We evaluated whether low-dose chemotherapy could improve effects of radiation therapy for glottic carcinoma with different prognostic factor based on the UICC 6th edition.
  • Fifty-one patients with T2N0 glottic carcinoma classified by the UICC 5th edition underwent chemoradiation therapy with low-dose CDDP (4 mg/m(2)) and oral UFT (450 mg of tegafur) continuing for four weeks (CRT group).
  • The historical control consisted of 49 patients treated with radiation therapy alone (RT group).
  • Forty-six tumors with the adjacent sign, i.e. tumors located adjacent to the thyroid cartilage on radiological examinations, were classified as T3 according to the 6(th) edition.
  • [MeSH-major] Cisplatin / administration & dosage. Glottis. Laryngeal Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546861.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Akimoto T, Nonaka T, Kitamoto Y, Ishikawa H, Ninomiya H, Chikamatsu K, Furuya N, Hayakawa K, Mitsuhashi N, Nakano T: Radiation therapy for T2N0 laryngeal cancer: A retrospective analysis for the impact of concurrent chemotherapy on local control. Int J Radiat Oncol Biol Phys; 2006 Mar 15;64(4):995-1001
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy for T2N0 laryngeal cancer: A retrospective analysis for the impact of concurrent chemotherapy on local control.
  • PURPOSE: The impact of concurrent chemotherapy on the local control in patients with T2N0 laryngeal cancer who receive radiation therapy (RT) was evaluated.
  • METHODS AND MATERIALS: Sixty-three patients with T2N0 laryngeal cancer who were treated by definitive RT were analyzed.
  • The primary site of the cancer was the glottis in 50 patients, the supraglottis in 9 patients, and the subglottis in 4 patients.
  • The multivariate analysis revealed that the treatment method (RT alone vs. CRT) was the most significant risk factor that predicted recurrence after RT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Analysis of Variance. Cisplatin / administration & dosage. Combined Modality Therapy / methods. Disease-Free Survival. Female. Glottis. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Survival Rate. Taxoids / administration & dosage. Voice Quality

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406396.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Nagahashi T, Fukuda S, Homma A, Yagi K, Furuta Y, Inuyama Y: Concurrent chemotherapy and radiotherapy as initial treatment for stage II supraglottic squamous cell carcinoma. Auris Nasus Larynx; 2001 May;28 Suppl:S95-8
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemotherapy and radiotherapy as initial treatment for stage II supraglottic squamous cell carcinoma.
  • OBJECTIVE: To evaluate the efficacy and safety of concurrent carboplatin (CBDCA) and radiotherapy for laryngeal carcinoma. we investigated survival rates and laryngeal preservation rates in patients with this treatment modality and those with radiation therapy only.
  • METHODS: We underwent chemotherapy with CBDCA and conventional radiotherapy concurrently to 17 patients with untreated stage II (T2NOM0) supraglottic squamous cell carcinoma since November 1990.
  • CBDCA (100 mg/m2) was administered intravenously once a week concurrently with radiotherapy (2.5 Gy/fr, 4 times a week).
  • At the dose of 40 Gy, the results were evaluated, and some of the patients underwent planned surgery and others continued the radiotherapy up to 65 Gy.
  • Compared with 14 cases of historical controls, which were treated by radiation therapy alone between 1988 and 1990, the cases with concurrent radiotherapy and chemotherapy had statistically significant advantage in overall successful laryngeal preservation rate (P < 0.05), whereas the two groups were not significantly different in the overall 5-year survival rate.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Glottis. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11683352.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Laccourreye O, Veivers D, Hans S, Ménard M, Brasnu D, Laccourreye H: Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders. Cancer; 2001 Sep 15;92(6):1504-11
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders.
  • BACKGROUND: The current studies documented the results achieved with chemotherapy alone with curative intent in a series of 67 patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders after a platin-based induction chemotherapy regimen.
  • METHODS: Group I consisted of 36 patients with tumors originating from the glottis.
  • Group II consisted of 31 patients with tumors originating from sites within the pharyngolarynx other than the glottis.
  • Statistical analyses of survival, local control, lymph node control, distant metastasis, and second primary tumor rates were based on the Kaplan-Meier life-table method.
  • Local control rates after salvage treatment were 100% in Group I patients and 83% in Group II patients.
  • Laryngeal preservation rates after salvage treatment were 100% in Group I patients and 64% in Group II patients.
  • CONCLUSIONS: The current report 1) contradicts the old dogma of nonchemocurability for invasive squamous cell carcinoma of the upper aerodigestive tract and 2) suggests that the use of a platin-based chemotherapy-alone regimen with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx who are classified as T1-T4N0M0 complete clinical responders after receiving an induction chemotherapy regimen is best indicated when the tumor originates from the glottis.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Drug Therapy, Combination. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Second Primary. Platinum / administration & dosage. Salvage Therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11745228.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 49DFR088MY / Platinum; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM: T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Oct 1;78(2):461-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy.
  • PURPOSE: To report the treatment outcomes of definitive radiotherapy (RT) for early-stage squamous cell carcinoma (SCCA) of the glottic larynx.
  • All patients had at least 2 years of follow-up, had histologic diagnosis of invasive SCCA, and received continuous-course RT.
  • None of these patients received chemotherapy or had elective nodal RT.
  • Multivariate analysis revealed that overall treatment time greater than 41 days (p = 0.001) and poorly differentiated histology (p = 0.016) adversely affected LC.
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Glottis / pathology. Glottis / surgery. Humans. Laryngectomy. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging / methods. Radiation Injuries / complications. Retrospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20153124.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Lai FY, Zhang Q, Guo ZM, Zeng ZY, Li H, Yu WB, Yang CS: [Treatment and prognosis of stage IV glottic laryngeal cancer]. Ai Zheng; 2008 Jan;27(1):71-4
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and prognosis of stage IV glottic laryngeal cancer].
  • This study was to explore the impacts of different treatment modalities, cervical lymph node status and surgical margin on the prognosis of stage IV glottic cancer.
  • The correlations of different treatment modalities, cervical lymph node status, and surgical margin to the prognosis of stage IV glottic cancer were analyzed.
  • There was no significant difference in survival rate among the patients received operation, operation plus postoperative radiotherapy, chemoradiotherapy, and operation plus chemotherapy (P=0.729).
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Glottis / pathology. Laryngeal Neoplasms / therapy. Laryngectomy / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184468.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Canadas KT, Baum ED, Lee S, Ostrower ST: Case report: Treatment failure using propanolol for treatment of focal subglottic hemangioma. Int J Pediatr Otorhinolaryngol; 2010 Aug;74(8):956-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: Treatment failure using propanolol for treatment of focal subglottic hemangioma.
  • Subglottic hemangioma is a rare, potentially life threatening tumor of infancy which poses serious treatment challenges.
  • A number of medical and surgical therapies over the years have met with variable success, and are associated with numerous potential morbidities.
  • A potential windfall in the management of infantile hemangiomas has arisen with the recent identification of propanolol as a highly efficacious and relatively safe new treatment modality.
  • At least five reports in the literature have described the rapid, successful treatment of airway hemangiomas with oral propanolol.
  • We describe the first reported treatment failure with propanolol for subglottic hemangioma in an infant who initially responded dramatically to the medication.
  • [MeSH-major] Hemangioma / drug therapy. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / pathology. Otorhinolaryngologic Surgical Procedures / methods. Propranolol / administration & dosage
  • [MeSH-minor] Female. Follow-Up Studies. Glottis / pathology. Humans. Infant. Laryngoscopy / methods. Laryngostenosis / diagnosis. Laryngostenosis / etiology. Retreatment. Risk Assessment. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20846505.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


12. Blanchet C, Nicollas R, Bigorre M, Amedro P, Mondain M: Management of infantile subglottic hemangioma: acebutolol or propranolol? Int J Pediatr Otorhinolaryngol; 2010 Aug;74(8):959-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment was efficient in two cases while an open procedure was necessary in the third child.
  • We also report a case of rebound growth after beta-mimetic drug use and the efficiency of propranolol treatment in such a recurrence.
  • Considering the lack of side effects and the advantages in terms of administration, we suggest acebutolol as a first-line treatment of subglottic hemangiomas for which intervention is required.
  • [MeSH-major] Acebutolol / administration & dosage. Hemangioma / drug therapy. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / surgery. Propranolol / administration & dosage
  • [MeSH-minor] Adrenergic beta-Antagonists / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Glottis / pathology. Humans. Laryngoscopy / methods. Laryngostenosis / diagnosis. Laryngostenosis / etiology. Sampling Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ACEBUTOLOL HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20557953.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 67P356D8GH / Acebutolol; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


13. El Hakim H, Waddell AN, Crysdale WS: Observations on the early results of treatment of recurrent respiratory papillomatosis using cidofovir. J Otolaryngol; 2002 Dec;31(6):333-5
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Observations on the early results of treatment of recurrent respiratory papillomatosis using cidofovir.
  • OBJECTIVE: To document the response of two patients with severe recurrent laryngeal papillomatosis following treatment with intralesional cidofovir in conjunction with carbon-dioxide laser evaporation.
  • METHODS: Retrospective review of treatment of two patients followed up over a 12-month period.
  • OUTCOME MEASURES: Photodocumentation and descriptive statistical representation of intervals between endoscopic treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Glottis / drug effects. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates. Organophosphorus Compounds / therapeutic use. Papilloma / drug therapy
  • [MeSH-minor] Child, Preschool. Female. Humans. Injections, Intralesional. Laser Therapy. Male. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12593542.001).
  • [ISSN] 0381-6605
  • [Journal-full-title] The Journal of otolaryngology
  • [ISO-abbreviation] J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  • [Number-of-references] 7
  •  go-up   go-down


14. Okubo M, Nishimura Y, Shibata T, Nakamatsu K, Kanamori S, Tachibana I, Koike R, Nishikawa T, Mori K: Definitive radiation therapy for moderately advanced laryngeal cancer: effects of accelerated hyperfractionation. Jpn J Clin Oncol; 2010 Oct;40(10):944-8
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiation therapy for moderately advanced laryngeal cancer: effects of accelerated hyperfractionation.
  • METHODS: Between 1998 and 2007, 9 supraglottic carcinomas (6 T2N0M0, 2 T2N2M0, 1 T3N0M0), 30 glottic carcinomas (25 T2N0M0, 5 T3N0M0), and 1 T2N0M0 subglottic carcinoma were treated with definitive radiotherapy using accelerated hyperfractionation without concurrent chemotherapy.
  • The dose-fractionation for 35 patients was 72.8 Gy/56 fractions/5.6 weeks, and that for four patients treated between 1998 and 2001 was 72 Gy/60 fractions/6 weeks.
  • One patient who had been treated with steroid therapy for systemic lupus erythematosus was treated by 67.8 Gy/44 fractions/4.4 weeks.
  • No late toxicities of grade 2 or more was noted among the 39 patients treated with 72.8 Gy/56 fractions or 72 Gy/60 fractions.
  • CONCLUSION: Accelerated hyperfractionation of 72.8 Gy/56 fractions/5.6 weeks using 1.3 Gy/fraction seems a safe and effective dose-fractionation for patients with moderately advanced laryngeal carcinomas.
  • [MeSH-major] Dose Fractionation. Glottis / radiation effects. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Dermatitis / etiology. Disease-Free Survival. Esophagitis / etiology. Female. Humans. Male. Middle Aged. Mucositis / etiology. Neoplasm Staging. Radiotherapy / adverse effects. Radiotherapy / methods. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534687.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


15. Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Mancuso AA: Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck; 2003 Jul;25(7):535-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
  • PURPOSE: To analyze parameters that may influence the likelihood of local control after definitive radiotherapy for head and neck cancer.
  • METHODS: Between April 1980 and January 2000, 404 patients were treated with definitive RT alone (358 patients) or combined with adjuvant chemotherapy (46 patients) at our institution and were followed up for 0.25 to 20.25 years (median, 3.5 years.
  • All patients had the primary tumor volume calculated on pretreatment CT.
  • Parameters evaluated in multivariate analyses of these end points included primary site, T stage, primary tumor volume, N stage, histologic differentiation, fractionation schedule, adjuvant chemotherapy, and gender.
  • RESULTS: The rates of local control and local control without a severe late complication after RT were significantly influenced by primary tumor volume for patients with cancer of the supraglottic larynx and true vocal cord.
  • In contrast, the rates of local control and local control without severe complications for patients with tumors of the oropharynx and hypopharynx were less influenced by tumor volume.
  • Multivariate analyses stratified by primary site revealed that tumor volume significantly influenced local control for patients with cancers of the supraglottis (p =.0220) and glottis (p =.0042) but not for those with lesions of the tonsillar fossa/posterior tonsillar pillar (p =.0892), base of tongue (p =.9493), anterior tonsillar pillar/soft palate (p =.5909), and hypopharynx (p =.2282).
  • Primary tumor volume also significantly influences the probability of local control in cancers of the supraglottis and glottis.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Radiotherapy / adverse effects. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc. Head Neck 25: 535-542, 2003
  • (PMID = 12808656.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Ansarin M, Planicka M, Rotundo S, Santoro L, Zurlo V, Maffini F, Alterio D, Cattaneo A, Chiesa F: Endoscopic carbon dioxide laser surgery for glottic cancer recurrence after radiotherapy: oncological results. Arch Otolaryngol Head Neck Surg; 2007 Dec;133(12):1193-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTERVENTIONS: Endoscopic laser surgery with curative intent using types III to V cordectomies according to the European Laryngological Association.
  • New recurrences developed in 13 patients (35%): 11 were treated by total laryngectomy, 1 by supracricoid laryngectomy, and 1 by chemotherapy.
  • CONCLUSIONS: Endoscopic laser surgery is a safe and effective salvage procedure in selected cases involving glottic recurrence after radiotherapy.
  • [MeSH-major] Glottis. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Laryngoscopy / methods. Laser Therapy / methods. Lasers, Gas. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Italy / epidemiology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086959.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Devlin JG, Langer CJ: Combined modality treatment of laryngeal squamous cell carcinoma. Expert Rev Anticancer Ther; 2007 Mar;7(3):331-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined modality treatment of laryngeal squamous cell carcinoma.
  • Early stage disease is best treated with radiation or surgery alone, but for patients with more locally advanced squamous cell carcinoma of the larynx, combined modality treatment has been shown to benefit selected patients, particularly when cisplatin-based chemotherapy and concurrent radiation therapy are employed, with or without altered fractionated radiation therapy.
  • The addition of induction chemotherapy to concurrent chemoradiotherapy is a promising treatment strategy that warrants further evaluation, but has not yet emerged as a standard of care; the toxicity of such regimens must be balanced with the potential benefits on a case-by-case basis, and functional outcomes are often quite variable.
  • Treatment planning, management and follow-up are complex, and thus should ideally be performed in a comprehensive, multidisciplinary fashion, in a center accustomed to a high volume of such cases.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Division / radiation effects. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Management. Glottis / pathology. Humans. Incidence. Laryngectomy / adverse effects. Meta-Analysis as Topic. Neck Dissection. Neoplasm Proteins / antagonists & inhibitors. Neoplasm Staging. Palliative Care. Positron-Emission Tomography. Quality of Life. Radiation-Sensitizing Agents / administration & dosage. Radiation-Sensitizing Agents / therapeutic use. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Treatment Outcome. Voice Disorders / etiology. Voice Disorders / prevention & control

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338653.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Radiation-Sensitizing Agents
  • [Number-of-references] 131
  •  go-up   go-down


18. Grandi C, Guzzo M, Cavina R, Gardani G, Tana S, Licitra L, Rossi N, Barbaccia C, Mingardo M, Fallahdar D, Bruno P, Molinari R: Treatment of cancer of the base of the tongue and glosso-epiglottic region: a multicenter Italian survey. GLOCC Group. Gruppo di Lavoro in Oncologia Cervico Cefalica. Tumori; 2000 May-Jun;86(3):215-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of cancer of the base of the tongue and glosso-epiglottic region: a multicenter Italian survey. GLOCC Group. Gruppo di Lavoro in Oncologia Cervico Cefalica.
  • BACKGROUND: The current treatment options for cancer of the base of the tongue and glosso-epiglottic region are surgery, radiotherapy, or a combination of both modalities.
  • Comparisons between different modalities are not common in the literature, and a real standard of treatment has not yet been established.
  • The purpose of our study was to evaluate the results of treatment in a large series of patients from 18 Italian institutions in relation to the main treatment adopted.
  • Survival was slightly better for patients with tumors of the glosso-epiglottic region than for those with a tumor of the base of the tongue.
  • Five-year disease-free survival was 55% for patients treated with surgery +/- radiochemotherapy and 26% for those submitted to radiotherapy alone or in combination with chemotherapy.
  • As far as the total dose and the treatment duration were concerned, only 26% of the patients of the radiotherapy group met the established criteria of adequacy, but in patients with adequate radiation the control rate was better only for small tumors (T1-T2).
  • [MeSH-major] Glottis. Laryngeal Neoplasms / therapy. Tongue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Dose Fractionation. Female. Humans. Italy. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Tongue cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10939602.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Nur DA, Oguz C, Kemal ET, Ferhat E, Sülen S, Emel A, Münir K, Ann CS, Mehmet S: Prognostic factors in early glottic carcinoma implications for treatment. Tumori; 2005 Mar-Apr;91(2):182-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in early glottic carcinoma implications for treatment.
  • AIM: In this study we aimed to determine the prognostic factors affecting local control (LC) in limited glottic carcinoma treated with definitive radiotherapy (RT).
  • MATERIAL AND METHODS: Between June 1991 and December 2001, 114 patients with early squamous-cell carcinoma of the glottis were treated with definitive RT at our institution.
  • A median dose of 66 Gy (50-70.2) was given over a median period of 46 days (20-60).
  • The prognostic parameters analyzed for LC were T classification, anterior commissure involvement, total RT dose, and overall treatment time.
  • In 15 patients with local failure, salvage treatment consisted of partial laryngectomy in eight patients and total laryngectomy in five.
  • In one of the three patients with regional failure, salvage surgery was applied and the other two were given palliative chemotherapy because of unresectable disease.
  • Following salvage treatments, the ultimate five-year LC rate was 96.9% and the five-year larynx preservation rate was 91.1%.
  • Only one patient developed distant metastases and two patients died of laryngeal cancer.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary. Prognosis. Recurrence. Retrospective Studies. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948549.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Farrag TY, Lin FR, Cummings CW, Koch WM, Flint PW, Califano JA, Broussard J, Bajaj G, Tufano RP: Neck management in patients undergoing postradiotherapy salvage laryngeal surgery for recurrent/persistent laryngeal cancer. Laryngoscope; 2006 Oct;116(10):1864-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No patients received concomitant or neo-adjuvant chemotherapy.
  • Reports of preRT and preSLS staging of the primary tumor and the neck, recorded using the TNM system, were reviewed.
  • The preRT staging of the primary tumor for those 34 patients showed that 32 (94%) were staged T-1 (14) and T-2 (18), whereas the preSLS staging of the primary tumor for those 34 patients showed that 29 (85%) were staged T-3 and T-4.
  • PreRT neck staging, preRT and preSLS staging of the primary tumor, along with laryngeal subsite involvement (supraglottis, glottis, subglottis) did not significantly correlate with the status of neck metastasis on final postSLS histopathology (P = .68, 0.78, 0.49, and 0.42, respectively).
  • None of the 34 patients had any neck tumor recurrence in the postSLS follow-up period (median, 3 yr).
  • In addition, all 17 patients who underwent SLS without neck dissection were staged N-0 both before RT as well as preSLS, and none developed neck disease in the postSLS follow-up period (median, 2.5 yr).
  • [MeSH-major] Laryngeal Neoplasms / surgery. Laryngectomy / methods. Neck Dissection. Neoplasm Recurrence, Local / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Elective Surgical Procedures. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17003711.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. León X, Quer M, Orús C, López-Pousa A, Pericay C, Vega M: How much does it cost to preserve a larynx? An economic study. Eur Arch Otorhinolaryngol; 2000;257(2):72-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various studies report an increase in costs when induction chemotherapy is included in the treatment of advanced laryngeal cancer, but to our knowledge no studies have yet compared the economic costs of total laryngectomy versus induction chemotherapy in the treatment of advanced laryngeal cancer.
  • We have conducted a retrospective study comparing the costs of treatment and survival in 96 patients with a T3N0-1 glottic carcinoma.
  • Findings showed that the average cost per patient in the group of patients treated by total laryngectomy with or without postoperative radiotherapy was 5,853 Eur, while that for the group of patients who began treatment with induction chemotherapy was 6,452 Eur.
  • The adjusted 5-year survival for patients treated with total laryngectomy with or without postoperative radiotherapy was 80%, and 72% for patients who began treatment with induction chemotherapy.
  • Sixteen of the 35 patients (46%) receiving induction chemotherapy were spared laryngectomy.
  • The use of induction chemotherapy in the treatment of patients with advanced laryngeal carcinomas involved an increase in cost of 600 Eur in relation to treatment with total laryngectomy and postoperative radiotherapy.
  • However, from an economic point of view, we consider induction chemotherapy to be an important consideration in an organ-preservation strategy.
  • [MeSH-minor] Chemotherapy, Adjuvant / economics. Chemotherapy, Adjuvant / statistics & numerical data. Cost-Benefit Analysis / economics. Cost-Benefit Analysis / statistics & numerical data. Glottis / pathology. Humans. Neoplasm Staging. Radiotherapy, Adjuvant / economics. Radiotherapy, Adjuvant / statistics & numerical data. Retrospective Studies. Spain / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10784365.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


22. Liu WS, Tang PZ, Qi YF, Xu ZG, Li ZJ: [Clinical analysis of 57 patients with poorly differentiated carcinomas of the supraglottic larynx]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Sep;39(9):562-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical characteristics, treatment and prognosis for poorly differentiated supraglottic carcinomas.
  • Of the 57 patients, 25 were treated with surgery alone, 9 with irradiation alone, 14 with surgery following preoperative radiation, 7 with postoperative radiation following surgery and 2 with surgery following preoperative chemotherapy.
  • Surgery was still the primary treatment for this disease and it was feasible to perform partial laryngectomy on certain patients.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Glottis / surgery. Laryngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606009.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Suzuki G, Hayabuchi N, Toda Y, Suefuji H, Ogo E, Nakajima T: [Laser-radiation therapy for T2N0M0 laryngeal-glottic cancer]. Nihon Igaku Hoshasen Gakkai Zasshi; 2002 Mar;62(4):151-5
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laser-radiation therapy for T2N0M0 laryngeal-glottic cancer].
  • PURPOSE: To evaluate the laser-radiation combined therapy for T2N0M0 laryngeal-glottic cancer in order to preserve the larynx.
  • METHODS AND MATERIALS: The subjects consisted of 52 patients with T2N0M0 laryngeal-glottic cancer treated with laser-radiation combined therapy between 1980 and 1999.
  • During this period, treatment was administered with different radiation devices(60Co or 4 MV-X ray), and 40-72 Gy (median, 60 Gy) of radiation therapy ware administered.
  • Tumor and treatment characteristics were correlated with local control at a median follow-up of 61 months(range 12-210 months).
  • Concurrent chemotherapy was administered to 32 patient; 29 were treated with 5-FU and vitamin A(FAR), and 3 were treated with low-dose CDDP.
  • Post treatment vocal function was examined in 37 patients.
  • The voice was evaluated in terms of four parameters: maximum phonation time (MPT), mean air flow rate during phonation over a comfortable duration(MFR), fundamental frequency range of phonation(F0 range), and sound pressure level range of phonation (SPL range).
  • Three of 4 patients who had locally relapsed were administered total laryngectomy as salvage therapy.
  • Concurrent chemotherapy was not a significant prognostic factor.
  • Laser debulking followed by radiation therapy did not change the voice significantly except the F0 range.
  • CONCLUSION: We conclude that the laser-radiation combined therapy for T2N0M0 laryngeal-glottic cancer was effective therapy for not only preservation of the voice but also for vocal function.
  • [MeSH-major] Glottis. Laryngeal Neoplasms / therapy. Laser Therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12043218.001).
  • [ISSN] 0048-0428
  • [Journal-full-title] Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica
  • [ISO-abbreviation] Nihon Igaku Hoshasen Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Rodrigo JP, Suárez C, Silver CE, Rinaldo A, Ambrosch P, Fagan JJ, Genden EM, Ferlito A: Transoral laser surgery for supraglottic cancer. Head Neck; 2008 May;30(5):658-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of treatment for supraglottic cancer is to achieve cure and to preserve laryngeal function.
  • Organ preservation strategies include both endoscopic and open surgical approaches as well as radiation and chemotherapy.
  • In addition, functional results of transoral laser resection are superior to those of the conventional open approach, in terms of the time required to restore swallowing, tracheotomy rate, incidence of pharyngocutaneous fistulae, and shorter hospital stay.
  • The management of the neck remains of paramount importance, as survival of patients with supraglottic cancer depends more on cervical metastasis than on the primary tumor.
  • The authors conclude that with careful selection of patients, laser supraglottic laryngectomy is a suitable, and often the preferred, treatment option for supraglottic cancer.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Laser Therapy / methods
  • [MeSH-minor] Glottis. Humans. Laryngectomy. Laryngoscopy. Neck Dissection. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18327778.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


25. Onakoya PA, Nwaorgu OG, Kokong DD, Adeosun AA, Ayodele KJ: Stomal recurrence post laryngectomy in University College Hospital, Ibadan. Afr J Med Med Sci; 2004 Mar;33(1):65-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Post-operatively, twelve patients (66.7%) had only radical radiotherapy; four (22.2%) had both radio-/ chemotherapy while two had preoperative and additional postoperative radiotherapy.
  • This present study also showed that advanced stage 3 and 4 tumour, transglottic involvement and the presence of preoperative tracheostomy are the likely risk factors that could be associated with recurrence in our environment.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy. Laryngectomy. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Glottis / pathology. Humans. Male. Middle Aged. Neck Dissection. Nigeria / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Tracheostomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15490797.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


26. Kumamoto Y, Masuda M, Kuratomi Y, Toh S, Shinokuma A, Chujo K, Yamamoto T, Komiyama S: "FAR" chemoradiotherapy improves laryngeal preservation rates in patients with T2N0 glottic carcinoma. Head Neck; 2002 Jul;24(7):637-42
Hazardous Substances Data Bank. VITAMIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The appropriate treatment approach for patients with T2N0 laryngeal cancer remains highly controversial.
  • Because radiotherapy alone is associated with a high risk of local recurrence, we have developed a triple combination treatment approach consisting of 5-fluorouracil (250 mg/day, i.v.
  • ), vitamin A (50,000 unit/day, i.m.) and external radiation (2.0 Gy/day), which we have termed "FAR therapy."
  • METHODS: Patients with T2N0 glottic carcinoma were initially treated with 15 days of FAR therapy, which included a cumulative radiation dose of 30Gy (i.e., "30 Gy of FAR therapy").
  • Those patients who demonstrated a complete response either clinically or pathologically continued to receive further FAR therapy, with up to 60-70 Gy.
  • All other patients received laryngectomy without any additional treatment.
  • RESULTS: Ninety-five patients were treated according to this program, and most of the patients (98%) were able to complete this treatment course.
  • Eighty-eight patients (93%) were treated with FAR therapy alone.
  • CONCLUSIONS: Because a high rate of laryngeal preservation was achieved without compromising disease-specific survival, our treatment approach based on FAR therapy may be promising for the treatment of patients with T2N0 glottic carcinoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Vitamin A / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Glottis. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Vitamin A.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc.
  • (PMID = 12112536.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 11103-57-4 / Vitamin A; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Taguchi T, Tsukuda M, Mikami Y, Horiuchi C, Ishitoya JI, Katori H: Concurrent chemoradiotherapy with carboplatin and uracil-ftegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx. J Laryngol Otol; 2006 Jun;120(6):478-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aimed to evaluate the efficacy and toxicity of concurrent chemoradiotherapy as a primary treatment modality for larynx preservation in patients with stage two squamous cell carcinoma (SCC) of the glottic larynx.
  • Radiotherapy was delivered five days a week using a once-daily fractionation of 2.0 Gray (Gy), to a total dose of 66-72 Gy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Glottis. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16563197.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; BG3F62OND5 / Carboplatin
  •  go-up   go-down


28. Byard RW, Gilbert JD: Narcotic administration and stenosing lesions of the upper airway--a potentially lethal combination. J Clin Forensic Med; 2005 Feb;12(1):29-31
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 2: A 48-year-old woman with severe narrowing of her glottic inlet from recurrent squamous cell carcinoma and an intravenous drug taking history was found dead at her home.
  • At autopsy there was evidence of recent and remote intravenous drug administration with marked narrowing of the glottis due to a recurrent tumor with a blood morphine level of 0.48 mg/L.
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Epstein-Barr Virus Infections / complications. Fatal Outcome. Female. Forensic Pathology. Glottis / pathology. Humans. Middle Aged. Migraine Disorders / drug therapy. Mouth Neoplasms / pathology. Mouth Neoplasms / surgery. Neoplasm Invasiveness. Substance Abuse, Intravenous / complications. Tonsillitis / virology

  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763687.001).
  • [ISSN] 1353-1131
  • [Journal-full-title] Journal of clinical forensic medicine
  • [ISO-abbreviation] J Clin Forensic Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Narcotics; 76I7G6D29C / Morphine
  •  go-up   go-down






Advertisement